鼻窦恶性肿瘤治疗后的SNOT-22子领域结局:一项前瞻性多中心研究
本研究前瞻性纳入多中心登记库中234例鼻窦恶性肿瘤患者,随访至治疗后5年,采用SNOT-22评估鼻窦生活质量子领域变化。鼻科、心理和睡眠子领域较基线显著改善(均p<0.05);辅助放化疗与鼻科、鼻外及耳/面部子领域结局较差相关。
要点
- 234例鼻窦恶性肿瘤患者平均随访22个月(3-64个月),鼻科、心理和睡眠子领域较基线显著改善(均p<0.05)。
- 40例全时间点随访患者中,鼻科、鼻外、心理和睡眠子领域显著改善,睡眠和心理子领域在2至5年间达到最小临床重要差异。
- 辅助放化疗与鼻科(校正比值比5.22 [1.69-8.66])、鼻外(2.21 [0.22-4.17])和耳/面部(5.53 [2.10-8.91])子领域结局较差相关。
核心结论
- 鼻窦恶性肿瘤治疗相关的鼻窦生活质量改善由鼻科、鼻外、心理和睡眠子领域驱动。
研究设计与样本
- 前瞻性多中心患者登记库研究,纳入234例鼻窦恶性肿瘤患者,在诊断时及治疗后随访至5年收集SNOT-22评分,采用多变量回归分析识别子领域变异驱动因素。
主要发现
- 234例患者平均随访22个月(3-64个月),鼻科、心理和睡眠子领域较基线显著改善(均p<0.05)。
- 40例全时间点随访患者亚组分析显示鼻科、鼻外、心理和睡眠子领域有统计学显著改善,睡眠和心理子领域在2至5年间达到最小临床重要差异。
- 辅助放化疗与鼻科(校正比值比5.22 [1.69-8.66])、鼻外(2.21 [0.22-4.17])和耳/面部(5.53 [2.10-8.91])子领域结局较差相关。
- 翼腭窝受累与鼻科(3.22 [0.54-5.93])和耳/面部(2.97 [0.32-5.65])子领域结局较差相关。
- 切缘阳性(5.74 [2.17-9.29])和手术入路联合与内镜相比(3.41 [0.78-6.05])与心理结局较差相关;辅助放疗(2.28 [0.18-4.40])与睡眠结局较差相关。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Patients with sinonasal malignancy (SNM) present with significant sinonasal quality of life (QOL) impairment. Global sinonasal QOL as measured by the 22-item Sinonasal Outcomes Test (SNOT-22) has been shown to improve with treatment. This study aims to characterize SNOT-22 subdomain outcomes in SNM. METHODS: Patients diagnosed with SNM were prospectively enrolled in a multi-center patient registry. SNOT-22 scores were collected at the time of diagnosis and through the post-treatment period for up to 5 years. Multivariable regression analysis was used to identify drivers of variation in SNOT-22 subdomains. RESULTS: Note that 234 patients were reviewed, with a mean follow-up of 22 months (3 months-64 months). Rhinologic, psychological, and sleep subdomains significantly improved versus baseline (all p < 0.05). Subanalysis of 40 patients with follow-up at all timepoints showed statistically significant improvement in rhinologic, extra-nasal, psychological, and sleep subdomains, with minimal clinically important difference met between 2 and 5 years in sleep and psychological subdomains. Adjuvant chemoradiation was associated with worse outcomes in rhinologic (adjusted odds ratio (5.22 [1.69-8.66])), extra-nasal (2.21 [0.22-4.17]) and ear/facial (5.53 [2.10-8.91]) subdomains. Pterygopalatine fossa involvement was associated with worse outcomes in rhinologic (3.22 [0.54-5.93]) and ear/facial (2.97 [0.32-5.65]) subdomains. Positive margins (5.74 [2.17-9.29]) and surgical approach-combined versus endoscopic (3.41 [0.78-6.05])-were associated with worse psychological outcomes. Adjuvant radiation (2.28 [0.18-4.40]) was associated with worse sleep outcomes. CONCLUSIONS: Sinonasal QOL improvements associated with treatment of SNM are driven by rhinologic, extra-nasal, psychological, and sleep subdomains.
引用
- Grimm DR, Beswick DM, Maoz SL, et al. SNOT-22 subdomain outcomes following treatment for sinonasal malignancy: A prospective, multicenter study. Int Forum Allergy Rhinol. 2024. PMID: 38372441. doi:10.1002/alr.23338
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。